2023 World Conference on Lung Cancer (Posters)-EP08.02. Neoadjuvant Immune Checkpoint Inhibitor plus Chemotherapy for Resectable Non-small Cell Lung Cancer in Real World

EP08.02. Neoadjuvant Immune Checkpoint Inhibitor plus Chemotherapy for Resectable Non-small Cell Lung Cancer in Real World - PDF(Slides)

Back to course

Pdf Summary

A real-world study was conducted to evaluate the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer (NSCLC) patients. The study included patients who received this treatment at the Affiliated Hospital of Zunyi Medical University from November 2020 to November 2022. The neoadjuvant regimen consisted of programmed cell death protein-1 (PD-1) inhibitors combined with platinum-based chemotherapy.<br /><br />The primary endpoint of the study was major pathological response (MPR), and the secondary endpoints included objective remission rate (ORR), pathological complete remission (pCR), clinical down-staging rate, and surgical outcomes. Out of the 32 patients who received neoadjuvant immunotherapy combined with chemotherapy, 19 achieved MPR and 16 achieved pCR. The ORR was 87.50%, and the clinical down-staging rate was 87.50%. The surgical outcomes were also positive, with a 93.75% R0 resection rate and no mortality within 30 or 90 days after surgery.<br /><br />The study also reported the occurrence of adverse events during the treatment period, with anemia, decreased neutrophil count, and increased alkaline phosphatase being the most common adverse reactions. However, most of the adverse events were grade 1-2.<br /><br />Overall, the study confirmed the feasibility and safety of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable NSCLC. However, the authors note that more prospective clinical trials are needed to further confirm these findings.

Asset Subtitle

Cheng Chen

Meta Tag

Speaker Cheng Chen

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

neoadjuvant immunotherapy

chemotherapy

non-small cell lung cancer

efficacy

safety

PD-1 inhibitors

pathological response

remission rate

surgical outcomes

adverse events